MedTrace Logo

Docosahexaenoic Acid (DHA) Supplementation in Amblyopia

NCT03402789 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2024-02-09

No results posted yet for this study

Summary

This study evaluates the addition of docosahexaenoic acid (DHA) to eye patching in the treatment of residual amblyopia in children ages 3 to 18 years old. Two thirds of participants will receive DHA along with eye patching, while one third of participants will receive a placebo along with eye patching.

Conditions

  • Amblyopia

Interventions

DRUG

Docosahexaenoic Acid

Docosahexaenoic acid 1,200mg daily plus 2 hours of eye patching daily

DRUG

Placebo Oral Tablet

Placebo tablet daily plus 2 hours of eye patching daily

Sponsors & Collaborators

Principal Investigators

  • Courtney Kraus, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2024-07-01
Completion
2024-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03402789 on ClinicalTrials.gov